225 related articles for article (PubMed ID: 11351347)
1. Caspase 3 expression in benign prostatic hyperplasia and prostate carcinoma.
O'Neill AJ; Boran SA; O'Keane C; Coffey RN; Hegarty NJ; Hegarty P; Gaffney EF; Fitzpatrick JM; Watson RW
Prostate; 2001 May; 47(3):183-8. PubMed ID: 11351347
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical analysis of Omi/HtrA2 expression in prostate cancer and benign prostatic hyperplasia.
Hu XY; Xu YM; Chen XC; Ping H; Chen ZH; Zeng FQ
APMIS; 2006 Dec; 114(12):893-8. PubMed ID: 17207090
[TBL] [Abstract][Full Text] [Related]
3. [Expression and significance of caspase-1 in benign hyperplastic prostate tissues].
Deng CH; Zang ZJ; Sun XZ; Huang XH; Wang H; Wang D; Su SH
Zhonghua Nan Ke Xue; 2005 Nov; 11(11):810-2. PubMed ID: 16333955
[TBL] [Abstract][Full Text] [Related]
4. Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression.
Royuela M; de Miguel MP; Ruiz A; Fraile B; Arenas MI; Romo E; Paniagua R
Eur Cytokine Netw; 2000 Mar; 11(1):119-27. PubMed ID: 10705309
[TBL] [Abstract][Full Text] [Related]
5. Resistance to apoptosis and up regulation of Bcl-2 in benign prostatic hyperplasia after androgen deprivation.
Cardillo M; Berchem G; Tarkington MA; Krajewski S; Krajewski M; Reed JC; Tehan T; Ortega L; Lage J; Gelmann EP
J Urol; 1997 Jul; 158(1):212-6. PubMed ID: 9186362
[TBL] [Abstract][Full Text] [Related]
6. Loss of caspase-1 and caspase-3 protein expression in human prostate cancer.
Winter RN; Kramer A; Borkowski A; Kyprianou N
Cancer Res; 2001 Feb; 61(3):1227-32. PubMed ID: 11221855
[TBL] [Abstract][Full Text] [Related]
7. Alpha-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone.
Leav I; McNeal JE; Ho SM; Jiang Z
Hum Pathol; 2003 Mar; 34(3):228-33. PubMed ID: 12673556
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis profiles in benign prostatic hyperplasia: close associations of cell kinetics with percent area density of histologic composition.
Zhang X; Zhang Q; Zhang Z; Na Y; Guo Y
Urology; 2006 Oct; 68(4):905-10. PubMed ID: 17070390
[TBL] [Abstract][Full Text] [Related]
9. Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia.
Shariat SF; Ashfaq R; Roehrborn CG; Slawin KM; Lotan Y
J Urol; 2005 Nov; 174(5):2046-50. PubMed ID: 16217391
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis-related gene expression in benign prostatic hyperplasia and prostate carcinoma.
Iacopino F; Angelucci C; Lama G; Zelano G; La Torre G; D'Addessi A; Giovannini C; Bertaccini A; Macaluso MP; Martorana G; Sica G
Anticancer Res; 2006; 26(3A):1849-54. PubMed ID: 16827116
[TBL] [Abstract][Full Text] [Related]
11. Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells.
Bass R; Perry B; Langenstroer P; Thrasher JB; Dennis KL; Tawfik O; Holzbeierlein J
J Urol; 2009 Feb; 181(2):615-9; discussion 619-20. PubMed ID: 19091346
[TBL] [Abstract][Full Text] [Related]
12. Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors.
Matsuyama M; Yoshimura R; Mitsuhashi M; Hase T; Tsuchida K; Takemoto Y; Kawahito Y; Sano H; Nakatani T
Int J Oncol; 2004 Apr; 24(4):821-7. PubMed ID: 15010818
[TBL] [Abstract][Full Text] [Related]
13. Immunoreactivity to caspase-3, caspase-7, caspase-8, and caspase-9 forms is frequently lost in human prostate tumors.
Rodríguez-Berriguete G; Galvis L; Fraile B; de Bethencourt FR; Martínez-Onsurbe P; Olmedilla G; Paniagua R; Royuela M
Hum Pathol; 2012 Feb; 43(2):229-37. PubMed ID: 21802116
[TBL] [Abstract][Full Text] [Related]
14. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate.
Steiner GE; Newman ME; Paikl D; Stix U; Memaran-Dagda N; Lee C; Marberger MJ
Prostate; 2003 Aug; 56(3):171-82. PubMed ID: 12772186
[TBL] [Abstract][Full Text] [Related]
15. Expression, localization and activity of neutral endopeptidase in cultured cells of benign prostatic hyperplasia and prostate cancer.
Albrecht M; Gillen S; Wilhelm B; Doroszewicz J; Aumüller G
J Urol; 2002 Jul; 168(1):336-42. PubMed ID: 12050566
[TBL] [Abstract][Full Text] [Related]
16. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium.
Wang W; Bergh A; Damber JE
Prostate; 2004 Sep; 61(1):60-72. PubMed ID: 15287094
[TBL] [Abstract][Full Text] [Related]
17. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer.
Zhigang Z; Wenlv S
Jpn J Clin Oncol; 2004 Jul; 34(7):414-9. PubMed ID: 15342669
[TBL] [Abstract][Full Text] [Related]
18. Human telomerase reverse transcriptase expression correlates with vascular endothelial growth factor-promoted tumor cell proliferation in prostate cancer.
Tang J; Wang Z; Li X; Li J; Shi H
Artif Cells Blood Substit Immobil Biotechnol; 2008; 36(2):83-93. PubMed ID: 18437586
[TBL] [Abstract][Full Text] [Related]
19. FGF17 is an autocrine prostatic epithelial growth factor and is upregulated in benign prostatic hyperplasia.
Polnaszek N; Kwabi-Addo B; Wang J; Ittmann M
Prostate; 2004 Jun; 60(1):18-24. PubMed ID: 15129425
[TBL] [Abstract][Full Text] [Related]
20. INSL3 in the benign hyperplastic and neoplastic human prostate gland.
Klonisch T; Müller-Huesmann H; Riedel M; Kehlen A; Bialek J; Radestock Y; Holzhausen HJ; Steger K; Ludwig M; Weidner W; Hoang-Vu C; Hombach-Klonisch S
Int J Oncol; 2005 Aug; 27(2):307-15. PubMed ID: 16010410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
